Daiichi Sankyo Co., Ltd.
https://www.daiichisankyo.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Daiichi Sankyo Co., Ltd.
Japan Drug Price Revision: Cuts, Increases Aim To Balance National Healthcare Costs
Japan will raise reimbursement prices for selected essential and clinically valuable drugs in April, while cutting back prices for a higher than usual number of other products through the broad application of market expansion repricing rules. The overall regular revision will see prices cut by 4.7% on average.
NASH: Madrigal Files Resmetirom In EU While US Action Date Closes In
Resmetirom, which could become the first approved treatment for non-alcoholic steatohepatitis, is among 11 new drugs that the European Medicines Agency has started to review for potential EU approval. Meanwhile, a decision on whether to approve the drug in the US is due on 14 March.
A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline
Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.
Abingworth Adds Stakes To Gilead’s Trodelvy Gamble
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Ambit Biosciences Corporation
- Asubio Pharmaceuticals, Inc.
- Daiichi Sankyo RD Novare Co., Ltd.
- Kitasato Daiichi Sankyo K.K.
- Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
- Plexxikon Inc.
- Ranbaxy Laboratories Ltd.
- Roxro Pharma, Inc.
- Sankyo Pharma
- Suntory Pharmaceutical
- U3 Pharma AG
- Daiichi Sankyo India Pharma Private Limited
- Kitasato Daiichi Sankyo Vaccine Co., Ltd.
- Zenotech Laboratories Ltd.
- Daiichi Sankyo Vietnam Company Limited.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice